山楂叶的化学成分

目的对蔷薇科山楂属植物山楂(Crataegus pinnatifidaBge.)的叶子部分的化学成分进行研究。方法运用硅胶、Sephadex LH-20柱色谱?ODS柱色谱、制备HPLC等分离手段进行化学成分的分离纯化,根据理化性质及波谱数据鉴定其结构。结果从山楂叶体积分数为80%乙醇的提取物中分离得到7个化合物。分别鉴定为18,19-seco,2α,3β,-dihydroxy-19-oxo-urs-11,13(18)-dien-28-oic acid(1)、3,9-dihydroxy-megastigma-5-ene(2)、(3S,5R,6R,7E)-megatsigmane-7-ene-3-hydrox-y-5,6-epoxy-9-O-β-D-glucopyranoside(3)、(Z)-3-hexenyl-6-O-β-D-xylopyranosyl-(1″-6′)-β-D-gluco-pyranoside(β-primeveroside)(4)、苯甲酸(5)、对羟基苯丙酸(6)、反式对羟基桂皮酸(7)。结论化合物1-4为首次从该属植物中分离得到,5-7为首次从该种植物中分离得到。     

鸡血藤化学成分的分离与结构鉴定

目的对中药鸡血藤(Spatholobus suberectus Dunn)中化学成分进行分离及结构鉴定。方法采用正相硅胶、反相ODS、Sephadex LH-20等柱色谱及高效液相色谱等手段进行分离纯化,并通过理化性质与波谱分析方法鉴定了化合物的结构。结果从鸡血藤体积分数为95%的乙醇提取物中分离鉴定了9个单体成分,分别为blumenol A(1)、(6S,7E,9R)-roseoside(2)、(6S,7E,9R)-6,9-dihydroxy-4,7-megastigman-3-one-9-O-[α-L-arabinopyranosyl-(1→6)-(β-D-glucopyranoside](3)、7S,8R-erythro-4,9,9'-trihydroxy-3,3'-dimethoxy-8-O-4'-neolignan-7-O-β-D-glucopyranoside(4)、(7S,8R)-dihydrodehydrodiconiferyl alcohol-4-O-(β-D-glucopyranoside(5)、(7S,8R)-3,3',5-trimethoxy-4',7-epoxy-8,5'-neolignan-4,9,9'-triol(6)、次黄苷(hypoxanthine-9-β-D-ribofuranoside,7)、烟酸(nicotinic acid,8)和丁二酸(amber acid,9)。结论其中2-8均为首次从密花豆属中分离得到的化合物。     

荷叶中化学成分的分离与鉴定

目的研究荷叶中的化学成分。方法采用正相硅胶、反相ODS、Sephadex LH-20等柱色谱及PHPLC法进行分离纯化,并通过理化性质、光谱分析方法及与文献对比,鉴定化合物的化学结构。结果从荷叶体积分数为70%的乙醇提取物中分离鉴定了8个化合物,其中有4个木脂素类:(+)-松脂醇[(+)-pinoresinol,1]、(+)-表松脂醇[(+)-epipinoresinol,2]、sylvatesmin(3)、(+)-异落叶松树脂醇[(+)-isolariciresinol,4];4个降倍半萜类:(3S,5R,6S,7E)-5,6-epoxy-3-hydroxy-7-me-gastigmen-9-one(5)、4,5-dihydroblumenol A(6)、(E)-3-oxo-retro-α-ionol(7)、(3S,5R,6R,7E,9S)-megastigman-7-ene-3,5,6,9-tetraol(8)。结论化合物1-8均为首次从莲属植物中分离得到。     

脚骨脆的化学成分研究

目的研究脚骨脆小枝和叶的化学成分。方法采用乙醇提取,提取物经萃取后以硅胶、凝胶和MCI等柱色谱法及高效液相色谱法进行分离纯化,采用波谱法进行结构鉴定。结果从该植物共分离得到8个化合物,其结构鉴定为:(6R,7E,9R)-9-hydroxymegastigm-4,7-dien-3-one,(6S,7E)-6-hydroxy-4,7-megastig-madiene-3,9-dione,(3S,5R,6S,7E)-5,6-epoxy-3-hydroxymegastigm-7-en-9-one,(6E,9S)-9-hydroxymegastigm-4,6-dien-3-one,caseamembrin A,casearlucin B,β-谷甾醇和胡萝卜苷。结论前6种化合物为首次从该植物中分离得到。     

天女木兰叶中甾类化合物的分离与鉴定

目的对天女木兰叶的化学成分进行分离和结构鉴定。方法采用硅胶、凝胶柱色谱和重结晶等分离方法对天女木兰叶的体积分数为90%的乙醇溶液提取物进行成分分离;通过谱学分析方法结合化合物理化性质对分离得到的化合物进行结构鉴定。结果分离得到8个化合物,分别鉴定为豆甾-4-烯-3,6-二酮(stigmast-4-en-3,6-dione,1),豆甾-4-烯-3β,6β-二醇(stigmast-4-en-3β,6β-diol,2),5α,8α-过氧-(22E,24R)-麦角甾-6,22-二烯-3β-醇[5α,8α-epidioxy-(22E,24R)-ergosta-6,22-dien-3β-ol,3],豆甾-4-烯-6β-羟基-3-酮(stigmast-4-en-6β-ol-3-one,4),β-谷甾醇(β-sitosterol,5),(22E,24R)-麦角甾-7,22-二烯-3β,5α,6β-三醇[(22E,24R)-ergosta-7,22-dien-3β,5α,6β-triol,6],豆甾-5-烯-3β,7α-二醇(stigmast-5-en-3β,7α-diol,7),胡萝卜苷(daucosterol,8)。结论化合物2-4、6、7为首次从木兰属植物中分离得到,化合物1为首次从该植物中分离得到。     

毛冬青中木脂素类化学成分的分离与鉴定

目的研究毛冬青中木质素类化学成分。方法采用硅胶柱色谱法、ODS柱色谱法、Sephedax LH-20柱色谱法、薄层色谱法及高效液相色谱法等方法对毛冬青体积分数70%乙醇提取物进行分离纯化,并根据理化性质及波谱数据鉴定分离得到化合物。结果分离得到10个木脂素类化合物,经鉴定分别为(7R,7′R,7″R,8S,8′S,8″S)-4′,4″-dihydroxy-3,3′,3″,5-tetramethoxy-7,9′:7′,9-diepoxy-4,8″-oxy-8,8′-sesquineolignan-7″,9″-diol(1)、erythro-(7S,8R)-1-(4-hydroxy-3-methoxyphenyl)-2-{4-[(E)-3-hydroxy-1-propenyl]-2-methoxyphe-noxy}-1,3-propanediol(2)、erythro-(7R,8S)-1-(4-hydroxy-3-methoxyphenyl)-2-{4-[(E)-3-hydroxy-1-propenyl]-2-methoxyphe-noxy}-1,3-propanediol(3)、erythro-(7R,8S)-guaiacylglycerol-β-coniferyl aldehyde ether(4)、erythro-(7S,8R)-guaiacylglycerol-β-coniferyl aldehyde ether(5)、Vladinol D(6)、7S,8R-dihydrodehydroconiferyl alcohol(7)、(-)-丁香酯素[(-)-syringaresinol,8]、(-)-杜仲树脂酚[(-)-medioresinol,9]、(+)-环橄榄树脂素[(+)-cyclo-olivil,10]。结论化合物1~7为首次从冬青属植物中分离得到。     

板栗种仁的化学成分(Ⅳ)

目的分离并鉴定板栗种仁的化学成分。方法采用硅胶柱色谱、凝胶柱色谱和重结晶等多种分离方法对板栗种仁的体积分数为95%的乙醇溶液回流提取物进行分离,并通过NMR、ESI-MS等多种谱学方法对分离得到的化合物进行结构鉴定。结果分离得到5个化合物,分别鉴定为(6S,9S)6-羟基-3-酮-α-紫罗兰醇-9-O-β-D-葡糖苷[(6S,9S)6-hydroxyl-3-oxo-α-ionol-9-O-β-D-glu-copyranoside,1]、(6S,9R)6-羟基-3-酮-α-紫罗兰醇-9-O-β-D-葡糖苷[(6S,9R)6-hy-droxyl-3-oxo-α-ionol-9-O-β-D-glucopyranoside,2]、5-羟基-2-羟甲基吡啶(5-hydroxyl-2-hydroxylm-ethylpyridine,3)、α-D-呋喃果糖甲苷(methyl-O-α-D-fructofuranoside,4)、正丁基-O-β-D-呋喃果糖苷(n-butyl-O-β-D-fructofuranoside,5)。结论这5个化合物均为首次从栗属植物中分离得到。     

短刺海马的化学成分研究

目的:研究短刺海马的化学成分。方法:采用乙醇提取和硅胶柱色谱、Sephadex LH-20柱色谱等手段对样品进行分离纯化,再通过波谱分析并结合文献对照,鉴定化合物的结构。结果:从短刺海马乙醇提取物中分离得到9个化合物,经鉴定为胆甾醇(1)、胆甾-4-烯-3-酮(2)、3β,5α,9α-三羟基-(22E,24R)-麦角甾-7,22-二烯-6-酮(3)、24-甲基-5α-胆甾-7,22-二烯-3β,5,6β-三醇(4)、3β-羟基-7-甲氧基-胆甾-5-烯(5)、3β-羟基-胆甾-5-烯-7-酮(6)、肌酸酐(7)、鸟嘧啶(8)、腺嘌呤(9)。结论:9个化合物均为首次从短刺海马中分离得到。该结果可为短刺海马的合理利用和进一步产品开发奠定物质基础。     

续断的化学成分研究

目的研究续断的化学成分。方法运用大孔树脂、反相硅胶及制备高效液相等色谱技术进行分离纯化,并根据理化性质和波谱数据鉴定化合物的结构。结果分离得到13个化合物,其中7个环烯醚萜苷和6个木脂素类化合物,分别鉴定为马钱苷(1)、獐牙菜苷(2)、6’-O-β-D-apiofuranosyl-sweroside(3)、续断苷H(4)、续断苷F(5)、续断苷E(6)、triplostoside A(7)、(7R,8S,7’R,8’S)-5-methoxyprinsepiol-4-O-β-D-glucopyranoside(8)、(7R,8S,7’R,8’S)-prinsepiol-4-O-β-D-glucopyranoside(9)、acanthoside D(10)、(7R,8S,7’R,8’S)-fraxiresinol-4’-O-β-D-glucopyranoside(11)、(7R,8S,7’R,8’S)-8-hydroxypinoresinol-4’-O-β-D-glucopyranoside(12)、(7R,8S,7’R,8’S)-8-hydroxypinoresinol-4-O-β-D-glucopyranoside(13)。结论其中化合物8、9、11、12、13为首次从川续断属植物中分离得到。     

甜瓜蒂化学成分的分离与鉴定

目的研究甜瓜蒂的化学成分。方法采用硅胶、ODS、凝胶、制备HPLC等多种色谱方法分离纯化,根据理化性质、波谱数据分析对分离得到的化合物进行结构鉴定。结果从甜瓜蒂中分离得到了7个化合物,分别鉴定为:粘霉烯醇(glutinol,1)、葫芦素B(cucurbitacin B,2)、葫芦素B-2-O-β-D-葡萄糖苷(2-O-β-D-glucopyranosy cucurbitacin B,3)、葫芦素D(cucurbitacin D,4)、(6S,9S)6-羟基-3-酮-α-紫罗兰醇-9-O-β-D-葡萄糖苷[(6S,9S)6-hydroxyl-3-oxo-α-ionol-9-O-β-D-glucopyranoside,5]、尿嘧啶核苷(uridine,6)和β-D-葡萄糖乙苷(ethyl-β-D-glucopyranoside,7)。结论化合物1、5、7均为首次从甜瓜属植物中分离得到,化合物6为首次从甜瓜蒂植物中分离得到。     

Efficacy of gut lavage,hemodialysis, and hemoperfusion in the therapy of paraquat or diquat intoxication

Clinical and in vitro investigations were carried out to test the efficacy of gut lavage, hemodialysis, and hemoperfusion in the treatment of poisoning with paraquat or diquat. In a patient suffering from diquat intoxication 130 times more diquat was removed by gut lavage 30 h after ingestion than was removed by complete aspiration of the gastric contents.Determination of in vitro clearances for paraquat and diquat by hemodialysis showed that, at serum concentrations of 1–2 ppm, such as are frequently encountered in poisoning in man, toxicologically relevant quantities of herbicide cannot be removed from the body. At a concentration of 20 ppm, on the other hand, hemodialysis proved to be effective, the clearance being 70 ml/min at a blood flow rate of 100 ml/min. The efficacy of hemoperfusion with coated activated charcoal was on the whole better. Especially at concentrations around 1–2 ppm, the clearance values for hemoperfusion were some 5–7 times higher than those for hemodialysis.In a patient suffering from paraquat poisoning, both hemodialysis as well as hemoperfusion were carried out. The in vitro results could be confirmed: At serum concentrations of paraquat less than 1 ppm no clearance could be obtained by hemodialysis while by hemoperfusion with activated charcoal quite high clearance values were measured and the serum level dropped down to zero.

---

Zusammenfassung Klinische Untersuchungen und Laboratoriumsversuche wurden durchgeführt, um die Wirksamkeit von Darmspülung, Hämodialyse und Hämoperfusion bei Paraquat- und Deiquat-Vergiftungen zu prüfen.Bei einem Patienten wurde 30 Std nach Deiquat-Aufnahme durch Darmspülung 130mal mehr Deiquat entfernt als durch vollständige Aspiration des Mageninhaltes. In vitro-Versuche ergaben, daß bei Blutserumkonzentrationen von 1–2 ppm, die bei Vergiftungen oft gemessen werden, durch Hämodialyse keine toxikologisch relevanten Paraquat- oder Deiquat-Mengen entfernt werden können. Dagegen erwies sich die Hämodialyse bei 20 ppm und einer Blutumlaufgeschwindigkeit von 100 ml/min mit einer Clearance von 70 ml/min als wirksam. Die Hämoperfusion mit beschicheter Aktivkohle war in diesen Versuchen aber eindeutig überlegen, denn insbesondere bei Konzentrationen um 1–2 ppm waren die Clearance-Werte 5–7mal höher als bei der Hämodialyse.Die in vitro-Ergebnisse wurden bei einem Patienten mit einer Paraquat-Vergiftung bestätigt: Bei Konzentrationen unter 1 ppm war die Hämodialyse wirkungslos, während durch Hämoperfusion relativ hohe Clearance-Werte erreicht wurden, so daß der Serumspiegel rasch unter die Nachweisgrenze abfiel.

     

Aquatic Insects and Trace Metals: Bioavailability,Bioaccumulation, and Toxicity

Abstract

The uptake of metals from food and water sources by insects is thought to be additive. For a given metal, the proportions taken up from water and food will depend both on the bioavailable concentration of the metal associated with each source and the mechanism and rate by which the metal enters the insect. Attempts to correlate insect trace metal concentrations with the trophic level of insects should be made with a knowledge of the feeding relationships of the individual taxa concerned. Pathways for the uptake of essential metals, such as copper and zinc, exist at the cellular level, and other nonessential metals, such as cadmium, also appear to enter via these routes. Within cells, trace metals can be bound to proteins or stored in granules. The internal distribution of metals among body tissues is very heterogeneous, and distribution patterns tend to be both metal and taxon specific. Trace metals associated with insects can be both bound on the surface of their chitinous exoskeleton and incorporated into body tissues. The quantities of trace meals accumulated by an individual reflect the net balance between the rate of metal influx from both dissolved and particulate sources and the rate of metal efflux from the organism. The toxicity of metals has been demonstrated at all levels of biological organization: cell, tissue, individual, population, and community. Much of the literature pertaining to the toxic effects of metals on aquatic insects is based on laboratory observations and, as such, it is difficult to extrapolate the data to insects in nature. The few experimental studies in nature suggest that trace metal contaminants can affect both the distribution and the abundance of aquatic insects. Insects have a largely unexploited potential as biomonitors of metal contamination in nature. A better understanding of the physico-chemical and biological mechanisms mediating trace metal bioavailability and exchange will facilitate the development of general predictive models relating trace metal concentrations in insects to those in their environment. Such models will facilitate the use of insects as contaminant biomonitors.     

Alzheimer’s disease – current trends in basic and clinical research. Highlights from the 16th ECNP

Advances in the molecular biological knowledge of neuronal nicotinic acetylcholine receptors (nAChRs) have led to a growing interest by the pharmaceutical industry in the development of novel compounds that selectively modulate nAChR function. The ability of (-)-nicotine, an activator of nAChRs, to enhance attentional aspects of cognition in animals and humans, to exert neuroprotective and anxiolytic-like effects, and presumably to mediate the negative correlation between smoking and Alzheimer's (and Parkinson's) Disease, has focused interest on the potential therapeutic utility of modulators of nAChR function for treatment of some of the deficits associated with these progressive, neurodegenerative conditions. Numerous compounds are known which activate nAChRs and which might serve as lead compounds toward the development of such agents. The pharmacologic diversity of neuronal nAChR subtypes suggests the possibility of developing selective compounds which would have more favourable side-effect profiles than existing agents. This broader class of agents, collectively called cholinergic channel modulators (ChCMs), is anticipated to encompass compounds which would have more favourable side-effect profiles than existing agents, which generally exhibit low selectivity. This selectivity may be achieved by preferentially activating some subtypes of nAChRs (i.e., Cholinergic Channel Activators, ChCAs) or inhibiting the function of other subtypes (Cholinergic Channel Inhibitors, ChCIs). An overview of the biology of nAChRs and the rationale for the use of ChCMs for the treatment of dementia related to neurodegenerative diseases are presented, followed by a discussion of lead compounds and compounds under consideration for clinical evaluation.     

2-(Acetoxyphenyl)-(Z)-styryl sulfides as cyclooxygenase inhibitors

2-(Acetoxyphenyl)-(Z)-styryl sulfides are described as selective cyclooxygenase-2 (COX-2) inhibitors, useful for treating inflammation and COX-2-mediated disorders including neoplasia. 2-(Acetoxyphenyl)-(Z)-styryl sulfide is claimed to be the most potent COX inhibitor in the series with a COX-2 selectivity ratio of 33. This compound is also claimed to be superior to celecoxib (Celebrex^®, Pfizer) in inhibiting cell growth of colorectal carcinoma cells. In this evaluation, the COX inhibitory activity of this compound is compared to that previously disclosed for diarylheterocycles and 2-(acetoxyphenyl)alkyl sulfides. The validity of the DLD-1 cell line in the growth inhibition studies is questioned based on recent literature reports indicating the lack of COX-2 expression in this cell line.     

Sleep-disordered breathing with chronic opioid use

Chronic opioid use for pain relief or as substitution therapy for illicit drug abuse is prevalent in our societies. In the US, retail distribution of methadone and oxycodone has increased by 824 and 660%, respectively, between 1997 and 2003. μ-Opioids depress respiration and deaths related to illicit and non illicit chronic opioid use are not uncommon. Since 2001 there has been an emerging literature that suggests that chronic opioid use is related to central sleep apnoea of both periodic and non-periodic breathing types, and occurs in ～ 30% of these subjects. The clinical significance of these sleep-related abnormalities are unknown. This review addresses the present knowledge of control of ventilation mechanisms during wakefulness and sleep, the effects of opioids on ventilatory control mechanisms, the sleep-disordered breathing found with chronic opioid use and a discussion regarding the future research directions in this area.     

Drug targets for cognitive enhancement in neuropsychiatric disorders

The investigation of novel drug targets for treating cognitive impairments associated with neurological and psychiatric disorders remains a primary focus of study in central nervous system (CNS) research. Many promising new therapies are progressing through preclinical and clinical development, and offer the potential of improved treatment options for neurodegenerative diseases such as Alzheimer's disease (AD) as well as other disorders that have not been particularly well treated to date like the cognitive impairments associated with schizophrenia (CIAS). Among targets under investigation, cholinergic receptors have received much attention with several nicotinic agonists (α7 and α4β2) actively in clinical trials for the treatment of AD, CIAS and attention deficit hyperactivity disorder (ADHD). Both glutamatergic and serotonergic (5-HT) agonists and antagonists have profound effects on neurotransmission and improve cognitive function in preclinical experiments with animals; some of these compounds are now in proof-of-concept studies in humans. Several histamine H3 receptor antagonists are in clinical development not only for cognitive enhancement, but also for the treatment of narcolepsy and cognitive deficits due to sleep deprivation because of their expression in brain sleep centers. Compounds that dampen inhibitory tone (e.g., GABA_A α5 inverse agonists) or elevate excitatory tone (e.g., glycine transporter inhibitors) offer novel approaches for treating diseases such as schizophrenia, AD and Down syndrome. In addition to cell surface receptors, intracellular drug targets such as the phosphodiesterases (PDEs) are known to impact signaling pathways that affect long-term memory formation and working memory. Overall, there is a genuine need to treat cognitive deficits associated with many neuropsychiatric conditions as well as an increasingly aging population.